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Phosphorylation of G protein-coupled receptors is a
critical step in the rapid termination of G protein sig-
naling. In rod cells of the vertebrate retina, phosphoryl-
ation of rhodopsin is mediated by GRK1. In cone cells,
either GRK1, GRK7, or both, depending on the species,
are speculated to initiate signal termination by phos-
phorylating the cone opsins. To compare the biochemi-
cal properties of GRK1 and GRK7, we measured the Km
and Vmax of these kinases for ATP and rhodopsin, a
model substrate. The results demonstrated that these
kinases share similar kinetic properties. We also deter-
mined that cAMP-dependent protein kinase (PKA) phos-
phorylates GRK1 at Ser21 and GRK7 at Ser23 and Ser36 in
vitro. These sites are also phosphorylated when FLAG-
tagged GRK1 and GRK7 are expressed in HEK-293 cells
treated with forskolin to stimulate the endogenous pro-
duction of cAMP and activation of PKA. Rod outer seg-
ments isolated from bovine retina phosphorylated the
FLAG-tagged GRKs in the presence of dibutyryl-cAMP,
suggesting that GRK1 and GRK7 are physiologically rel-
evant substrates. Although both GRKs also contain
putative phosphorylation sites for PKC and Ca2/cal-
modulin-dependent protein kinase II, neither kinase
phosphorylated GRK1 or GRK7. Phosphorylation of
GRK1 and GRK7 by PKA reduces the ability of GRK1
and GRK7 to phosphorylate rhodopsin in vitro. Since
exposure to light causes a decrease in cAMP levels in
rod cells, we propose that phosphorylation of GRK1 and
GRK7 by PKA occurs in the dark, when cAMP levels in
photoreceptor cells are elevated, and represents a novel
mechanism for regulating the activities of these kinases.
G protein-coupled receptors (GPCRs)1 belong to the largest
family of signal-transducing proteins in eukaryotes. They me-
diate cellular responses to a variety of environment stimuli,
including light, taste, odorants, ions, nucleotides, peptides, and
lipids, through the activation of heterotrimeric G proteins (1–
4). Phosphorylation of ligand-activated GPCRs by G protein-
coupled receptor kinases (GRKs) is the initial step in the rapid
termination or desensitization of GPCR signal transduction.
For example, in rod cells of the vertebrate retina, desensitiza-
tion occurs when light-activated rhodopsin is phosphorylated
by GRK1, followed by the binding of visual arrestin to the
phosphorylated rhodopsin, which blocks its interaction with
transducin, the rod cell G protein (5). Although desensitization
also occurs in cone cells, less is known about the proteins
involved and their regulation. GRK1 and a cone-specific GRK,
GRK7, are coexpressed in human and monkey cone cells (6–8)
where both may contribute to the deactivation of cone opsins
(7–9). In contrast, only GRK7 is expressed in the cones of pigs
and dogs. However, it is absent from the mouse genome alto-
gether and mouse cones express only GRK1 (7). Therefore,
differences in cone visual transduction between species may
result in part from variations in the expression pattern of
GRK1 and GRK7. We recently implicated GRK7 in the phos-
phorylation of cone opsins in retinas from the pig and the
13-lined ground squirrel, rod-dominant and cone-dominant
mammals, respectively (10). These results suggest that the role
of GRK7 in cones might be similar to the role of GRK1 in rods.
Very little is known regarding the regulation of GRKs in the
retina apart from the interaction of GRK1 with recoverin, a
retina-specific Ca2 sensor protein that inhibits the binding of
GRK1 to rhodopsin (11). Since both GRK1 and GRK7 may
phosphorylate cone opsins in primates, a comparison of their
enzyme activities and their regulation by other signaling mol-
ecules is essential for understanding their potential contribu-
tions to cone opsin deactivation.
In this report, we compare the activities of human GRK1 and
GRK7 in vitro. GRK1 and GRK7 share a similar Km and Vmax
for bovine rhodopsin, a model GPCR substrate. We also deter-
mined that PKA phosphorylates the amino termini of GRK1
and GRK7, resulting in reduced ability of these two kinases to
phosphorylate rhodopsin in vitro. Because cAMP levels are
regulated by light in photoreceptor cells (12–15), our results
provide the basis for a novel mechanism whereby GRK1 and
GRK7 activities may be regulated by PKA in a light-dependent
manner. Phosphorylation by second messenger-regulated ki-
nases has been reported to regulate the activities of GRK2 and
GRK5 (16–19) and now appears to be a common posttransla-
tional modification that alters the activities of the retina-spe-
cific GRK family members.
EXPERIMENTAL PROCEDURES
Expression and Purification of Human FLAG-GRK1 and FLAG-
GRK7—The FLAG amino acid sequence (Sigma), DYKDDDDK, was
placed at the amino terminus of GRK1 and GRK7 by PCR amplification.
Point mutations in GRK1 and GRK7 were generated by site-directed
PCR mutagenesis using the QuikChange® multi site-directed mutagen-
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esis kit (Stratagene, La Jolla, CA). Mutagenesis was confirmed by
sequence analysis. HEK-293 cells were transfected using the diethyl-
aminoethyl dextran method as described previously (20). After 72 h in
medium supplemented with 1 mM mevalonolactone (Sigma), the cells
were lysed in Tris-buffered saline (TBS) containing 0.5% n-dodecyl
maltoside, 1 g/ml leupeptin, and 1 g/ml aprotinin followed by cen-
trifugation at 40,000  g for 30 min at 4 °C. The supernatants were
incubated with anti-FLAG M2 affinity resin (Sigma) for 4 h at 4 °C and
washed six times by centrifugation with TBS. The GRKs were eluted
with FLAG peptide according to directions from the manufacturer. The
eluted FLAG-GRKs were separated by SDS-PAGE (21) and stained
with SYPRO Red (Molecular Probes, Eugene, OR). The purified GRKs
were visualized with a STORM imaging system (Amersham Bio-
sciences). Protein concentrations and purity were determined using a
concentration curve of bovine serum albumin as a standard. The GRKs
were stored at 4 °C or at 20 °C in 50% glycerol. Experiments were
performed within 2–3 weeks using batches of GRKs isolated at the same
time to prevent errors due to different storage times.
Isolation of Urea-stripped Rod Outer Segment (UROS) Membranes
from Bovine Retina—Procedures were performed under dim red light
(Kodak No. 2 Safelight). Frozen dark-adapted bovine retinas (J. A.
Lawson, Inc., Lincoln, NB) were homogenized in 20 mM Tris-HCl, pH
7.5, 1 mM CaCl2 (Buffer A) containing 45% sucrose (v/v), followed by
centrifugation at 15,000 rpm for 25 min in a Beckman JA-17 rotor to
collect the rod outer segments by flotation. The supernatant was diluted
with 2 volumes of Buffer A and centrifuged at 14,000 rpm in a Beckman
JA-14 rotor. After resuspending the membrane pellet in Buffer A, the
membranes were layered over a sucrose gradient (25–30%, v/v in Buffer
A) and centrifuged at 27,000 rpm for 30 min using a Beckman SW 28
rotor. The membranes collected from the interface were washed three
times by centrifugation at 14,000 rpm in a Beckman Ti70 rotor for 30
min in 20 mM Tris-HCl, pH 7.5, 100 mM NaCl, 5 mM MgCl2, and 1 mM
EDTA, followed by three washes in 20 mM Tris-HCl, pH 7.5, and 1 mM
EDTA. The membranes were homogenized in 50 mM HEPES, pH 8.0, 5
M urea, 5 mM EDTA, and 0.5 mM DTT and incubated for 1 h at 4 °C.
After 5-fold dilution in 20 mM HEPES, pH 8.0, 2 mM EDTA, and 0.5 mM
DTT, the membranes were centrifuged at 45,000 rpm in a Beckman
Ti70 rotor and washed four times in 20 mM Tris-HCl, pH 7.5, 1 mM
EDTA, 2 mM MgCl2, and 0.5 mM DTT. The membranes were resus-
pended in 20 mM HEPES, pH 8.0, 2 mM EDTA, and 0.5 mM DTT and
stored at 80 °C. To determine the concentration of rhodopsin, UROS
membranes were solubilized in 2% CHAPS in the dark with 20 mM
hydroxylamine and the absorption spectrum measured before and after
bleaching under bright fluorescent light for 10 min as described (20).
After subtracting the rhodopsin spectrum (normalized at 700 nm) meas-
ured in the light from the spectrum measured in the dark, the concen-
tration of rhodopsin was calculated using a molar extinction coefficient
of 42,700 M1 cm1 at 498 nm (22).
In Vitro Phosphorylation of Bovine Rhodopsin—UROS membranes
containing bovine rhodopsin were used as a substrate for phosphoryl-
ation by FLAG-tagged GRK1 and GRK7. Rhodopsin phosphorylation
was measured by incubating UROS membranes in 25 l of buffer
containing 20 mM Tris-HCl, pH 7.0, 6 mM MgCl2, and [-
32P]ATP
concentrations as indicated in the legends to Figs. 1, 2, 10, and 11 in the
presence or absence of light at 30 °C. Assays were performed in tripli-
cate and 10-l aliquots of each reaction were spotted onto P81 What-
man® phosphocellulose discs (Whatman International Ltd., Maidstone,
UK), dried, and washed three times in 50 mM phosphoric acid and once
in acetone. Phosphorylation of rhodopsin was quantified by the Ceren-
kov method. Kinetic parameters were determined by nonlinear regres-
sion analysis (GraphPad PRISM, San Diego, CA) after subtracting the
level of phosphorylation measured in the dark from the level of phos-
phorylation in the light. For determination of the Km and Vmax for ATP,
50 nM GRK1 or GRK7 was incubated for 2 min with 10 M rhodopsin
and 10–400 M ATP. The ATP concentration was determined spectro-
photometrically. For determination of the Km and Vmax for rhodopsin,
50 nM GRK1 or GRK7 was incubated for 2 min with 300 M [-32P]ATP
(500–1000 cpm/pmol) and 0.2–12.5 M rhodopsin. The phosphorylation
of rhodopsin was linear during this time period, as demonstrated in Fig.
1C. In some experiments, phosphorylation of rhodopsin by GRK1 and
GRK7 was measured after phosphorylation of the GRKs by the catalytic
subunit of PKA (100 units/l reaction mixture, New England Biolabs
Inc., Beverly, MA). GRKs (50 nM) were incubated with or without PKA
catalytic subunit for 10 min at 30 °C. Rhodopsin (2 M) was added for an
additional 2 min, and the reactions were stopped by spotting aliquots
onto P81 Whatman® phosphocellulose discs. Phosphorylation was mon-
itored by the Cerenkov method.
In Vitro Phosphorylation of GRK1 and GRK7—Phosphorylation by
PKA was measured in vitro by incubating the catalytic subunit of PKA
(100 units/l reaction mixture, New England Biolabs Inc.) at 30 °C with
wild-type or mutant FLAG-tagged GRK1 and GRK7 (500 ng) and 150
M [-32P]ATP (500–1000 cpm/pmol) in a 50-l reaction volume for 30
or 60 min as described in the legends to Figs. 3 and 7. Proteins were
separated by SDS-PAGE or spotted onto P81 Whatman® phosphocel-
lulose discs, washed as described above, and quantified using the Ce-
renkov method to determine the amount of phosphorylation. Phospho-
rylation by PKC (Invitrogen) was assessed using a mixture of
phosphatidylserine (Sigma) and diacylglycerol (Avanti Polar Lipids,
Inc., Alabaster, AL) as described by the manufacturer. Histone (H1)
Type III (Sigma) was used as a control substrate to monitor PKC
activity. Phosphorylation of GRK1 and GRK7 by Ca2/calmodulin-de-
pendent protein kinase II (CaMKII) (Calbiochem) was measured in the
presence of calmodulin (Calbiochem). Syntide 2 (Sigma) was used as a
control substrate to monitor CaMKII activity.
In Situ Phosphorylation of GRK1 and GRK7—Phosphorylation of
wild-type and mutant GRK1 and GRK7 was assessed after transient
expression of the proteins in HEK-293 cells using the Lipofectamine
Plus transfection method (Invitrogen). Three days after transfection,
cells were washed in phosphate-free DMEM and preincubated with
phosphate-free DMEM containing 0.1% serum for 30 min. Cells were
washed in phosphate-free DMEM and preincubated with
[32P]orthophosphate (100 Ci/ml) in phosphate-free DMEM for 1 h.
Cells were incubated with 25 M forskolin (Sigma) in Me2SO or Me2SO
only for 15 min, then lysed for 30 min at 4 °C in TBS containing 1%
Triton X-100, 1 g/ml leupeptin, 1 g/ml aprotinin, 50 mM NaF, 1 mM
EDTA, and 10 mM sodium pyrophosphate. The lysates were centrifuged
at 40,000  g and incubated with anti-FLAG M2 affinity resin for 4 h at
4 °C. The resin was washed five times with TBS and incubated with
Laemmli buffer before separation by SDS-PAGE (21). Phosphorylation
was visualized by phosphorimage analysis using a STORM imaging
system. The expression levels of the GRKs were compared by Western
blot analysis using the anti-FLAG M2 monoclonal antibody (Sigma) and
the Western-StarTM protein detection kit (Applied Biosystems, Foster
City, CA) for chemiluminescence detection.
Phosphorylation of FLAG-tagged GRKs by PKA from Rod Outer
Segments—ROS were isolated from frozen dark-adapted bovine retina
(J. A. Lawson, Inc.) using a stepwise sucrose density gradient as de-
scribed (23, 24). Phosphorylation of FLAG-tagged GRK1 and GRK7 was
performed under dim red light using methods described previously (25)
with the following modifications. ROS containing 20 M rhodopsin were
resuspended in 20 mM Tris-HCl, pH 7.6, 50 mM NaCl, 1 mM MgCl2, and
0.1% Triton X-100. FLAG-tagged GRK or GRK7 (1 g) and 5 M
[-32P]ATP (30 Ci) were added to the ROS and incubated in the
presence or absence of 200 M dibutyryl cyclic AMP (Bt2cAMP) and 10
M H-89 (Sigma) for 30 min at 37 °C. The reaction was terminated with
lysis buffer containing 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM
EDTA, 1% Triton X-100, 1 protease inhibitor mixture (Sigma), and 10
mM NaF. After centrifugation of the ROS lysates for 15 min at 45,000
rpm in a Beckman TLA45 rotor, the supernatant was incubated with
anti-FLAG M2 affinity resin for 2 h at 4 °C. The resin was washed with
lysis buffer, incubated with Laemmli buffer, and the extracted proteins
were separated by SDS-PAGE. The gels were transferred to nitrocellu-
lose membrane and phosphorylation was observed by phosphorimage
analysis. Western blot analysis was performed with the same nitrocel-
lulose membrane using the anti-FLAG M2 monoclonal antibody and a
chemiluminescent detection system as described above.
Chemical Cleavage of GRK1—FLAG-tagged GRK1 (10 g) was incu-
bated with or without PKA catalytic subunit and 10 M [-32P]ATP (10
Ci/reaction) for 30 min at 30 °C. Chemical digestion of GRK1 with 70%
formic acid was performed at 37 °C for 48 h while shaking. Cleavage of
GRK1 with iodosobenzoic acid was performed after heating GRK1 at
70 °C for 10 min with 0.1% SDS (final concentration). The heated
samples were diluted with water (1:1, v/v) prior to the addition of
iodosobenzoic acid (2 mg/ml in acetic acid, final concentration). The
cleavage reaction was incubated under N2 in the dark for 48 h at room
temperature. After chemical digestion with formic acid or iodosobenzoic
acid, the reaction mixtures were subjected to five wash cycles with
water by SpeedVac lyophilization, resuspended in 500 mM Tris-HCl, pH
8.0, and analyzed using a 4–12% NuPAGE gel system.
Two-dimensional Chromatography of GRK1 and GRK7—Peptide
maps were generated using proteins radiolabeled in vitro or in situ as
described by Boyle et al. (26) and Schaller and Parsons (27). For in vitro
experiments, 1–2 g of GRK1 or GRK7 were incubated with PKA
catalytic subunit (100 units/l reaction mixture, New England Biolabs
Inc.) and 10 M [-32P]ATP (10 Ci/reaction) at 30 °C for 30 min.
Phosphorylated proteins were separated by SDS-PAGE and transferred
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to nitrocellulose. The radioactive bands were excised and incubated
with 0.5% polyvinylpyrrolidone in 100 mM acetic acid for 30 min at
37 °C. After washing with distilled water, the nitrocellulose was incu-
bated with either 20 g trypsin (GRK1) or chymotrypsin (GRK7) in 50
mM ammonium bicarbonate for 16 h at 37 °C. Following proteolysis, the
reaction mixture was lyophilized and washed with distilled water by
centrifugation in a SpeedVac. The GRK1 peptides were separated by
thin layer electrophoresis (TLE) for 9–12 min at 1000 V in 0.126 M
ammonium bicarbonate buffer, pH 8.9, using a Hunter thin layer pep-
tide mapping system (CBS Scientific, Del Mar, CA). The GRK7 peptides
were separated by TLE in pH 1.9 buffer (88% formic acid:acetic acid:
H2O, 25:78:897, v/v/v). The plates were dried and subjected to ascending
TLC in chromatography buffer (butanol:acetic acid:pyridine:H2O:isobu-
tyric acid, 2:3:5:29:65, v/v/v/v/v). The chromatography plates were dried
and exposed to x-ray film to visualize the phosphopeptides.
RESULTS
Comparison of the Kinetic Parameters of GRK1 and
GRK7—A comparison of the enzymatic activities of GRK1 and
GRK7 may help distinguish their potential roles in cone opsin
desensitization. FLAG-tagged human GRK1 and GRK7 were
purified from transiently transfected HEK-293 cells using af-
finity chromatography. One contaminating band is visible at
67 kDa on SDS-polyacrylamide gels (Fig. 1A). The positions of
the FLAG-tagged GRKs were confirmed by immunoblot anal-
ysis of the same sample using an anti-FLAG antibody (data not
shown). GRK1 exhibited a slightly higher mobility than GRK7,
although its predicted molecular size is slightly larger (64.8
kDa for FLAG-GRK1 and 63.5 kDa for FLAG-GRK7). Both
kinases were composed of 2–3 bands, possibly due to heteroge-
neous isoprenylation or phosphorylation. The expressed pro-
teins were 70–80% pure (Fig. 1B). To measure the activities
of these kinases in vitro, UROS membranes containing bovine
rhodopsin were used as a model substrate. Rhodopsin was
selected as a substrate because of its ease of isolation in large
quantities from bovine retina. In contrast, the cone opsins
cannot be isolated in sufficient amounts for these studies. The
cone opsins possess serine/threonine-rich carboxyl termini that
serve as substrates for phosphorylation (28, 29). Similarly,
rhodopsin possesses seven serines and threonines in the car-
boxyl terminus that serve as substrates for GRK1 (5). To define
the appropriate conditions for analyzing the activities of these
kinases, a time course of rhodopsin phosphorylation by GRK1
and GRK7 was performed (Fig. 1C). The results demonstrated
that phosphorylation reaches a plateau in 60 min and the
reaction is linear for at least 2 min (Fig. 1C, inset). Phospho-
rylation of rhodopsin in the dark by either GRK1 or GRK7 was
negligible over the 60-min time period (data not shown). There-
fore, a 2-min assay was used for all subsequent experiments.
The kinetic parameters of GRK1 and GRK7 were determined in
vitro for ATP (Fig. 2A) and rhodopsin (Fig. 2B) and are sum-
marized in Table I. GRK7 has a Km for ATP (21.4 M) that is
twice that of GRK1 (10.6 M). The Km values for rhodopsin
FIG. 1. Rhodopsin phosphorylation
by GRK1 and GRK7. A, FLAG-tagged
GRK1 and GRK7 purified from HEK-293
cells by affinity chromatography as de-
scribed under “Experimental Procedures”
were chromatographed by SDS-PAGE
and stained with SYPRO Red to allow
visualization of the kinases. Lane 1, 1 g
of bovine serum albumin; lane 2, 1 g of
FLAG-GRK1; lane 3, 1 g of FLAG-
GRK7. B, the percent purity of wild-type
(WT) and mutant GRK1 and GRK7, pre-
pared as described for A, was estimated
by measuring the SYPRO Red staining of
the GRK-specific band compared with the
level of staining in the entire lane. C,
FLAG-tagged GRK1 (106 ng) and GRK7
(39 ng) were incubated with 2 M rhodop-
sin and 150 M [-32P]ATP (500–1000
cpm/pmol) for the indicated times at
30 °C. The amount of phosphorylation
was determined by Cerenkov counting as
described under “Experimental Proce-
dures.” Phosphorylation in the dark was
subtracted from phosphorylation in the
light. Inset, the first 2 min of the time
course is shown on an expanded scale to
demonstrate the linearity of the reaction.
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were 1.9 M and 3.5 M for GRK7 and GRK1, respectively.
GRK7 and GRK1 also display similar catalytic activities and
phosphorylate rhodopsin with a Vmax of 916 and 1132 nmol/
min/mg kinase, respectively. The Km values for ATP and rho-
dopsin reported here are similar to those reported by Palcze-
wski and colleagues using bovine GRK1 to phosphorylate
bovine rhodopsin in membranes (30, 31). The affinity of GRK1
for detergent-solubilized rhodopsin reported by Thurmond et
al. (32) is 10-fold higher (0.45 M) than the affinity of GRK1 for
rhodopsin measured in our experiments. Their studies also
reported a lower Vmax for detergent-extracted rhodopsin. Al-
though the use of rhodopsin in membranes represents a more
physiological substrate than detergent-extracted proteins, the
interpretation of such measurements is limited, due to several
factors. For example, varying the amount of rhodopsin in the
assay also varies the amount of membrane. Since these GRKs
may partition into the membrane, the resulting Km values also
may reflect changes that occur with increasing amounts of
membrane. In addition, since all seven serines and threonines
in bovine rhodopsin (six in human rhodopsin) have been shown
in vitro and in vivo to serve as phosphorylation substrates (5,
33–34), it is likely that the rhodopsin in our assays represents
a heterogeneously phosphorylated population. Nevertheless,
our results indicate that GRK1 and GRK7 share similar enzy-
matic activities toward rhodopsin and ATP.
GRK1 and GRK7 Are Substrates for PKA in Vitro—Amino
acid sequence analysis suggests that GRK1 and GRK7 have a
number of potential PKA phosphorylation sites. In the absence
of PKA, GRK1 and GRK7 are autophosphorylated, as reported
previously (6, 36). When incubated with the catalytic subunit
of PKA, wild-type GRK1 and GRK7 demonstrated increased
levels of phosphorylation (Fig. 3A). Kinase-inactive GRK1
(K219R) and GRK7 (K220R) mutants were generated for com-
parison with the wild-type proteins to distinguish between
autophosphorylation and phosphorylation by PKA. The corre-
sponding kinase-inactive GRK2 mutant acts as a dominant
negative and cannot phosphorylate the 2-adrenergic receptor
(37, 38). Similarly, the kinase-inactive mutants, K219R-GRK1
and K220R-GRK7, are unable to phosphorylate rhodopsin in
vitro (data not shown). These mutants do not undergo auto-
phosphorylation but can be phosphorylated by PKA (Fig. 3A). A
comparison of the amino acid sequences of human GRK7 and
GRK1 suggests that GRK7 has a conserved autophosphoryla-
tion site at Ser490 (7). The mutants, S490A-GRK7 and S490E-
GRK7, do not undergo autophosphorylation, indicating that
Ser490 is the only autophosphorylation site in GRK7 (Fig. 3B).
Mutation of this serine to alanine or glutamic acid does not
reduce phosphorylation by PKA (Fig. 3B). Therefore, the site(s)
in GRK7 phosphorylated by PKA is distinct from the GRK7
autophosphorylation site.
There are also potential phosphorylation sites for PKC and
CaMKII in the sequences for GRK1 and GRK7. However,
PKC, a calcium and lipid-dependent Ser/Thr kinase present
in rod outer segments (39–42), does not phosphorylate GRK1
or GRK7 in vitro (data not shown). Likewise, CaMKII, which is
abundant in neural tissues (43) and fish photoreceptor cells
(44), phosphorylates phosducin (45) but does not phosphorylate
GRK1 or GRK7 in vitro (data not shown). PKC and CaMKII
phosphorylated the control substrates histone H1 and syntide
2, respectively, indicating that both kinases were active in our
assay (data not shown).
GRK1 and GRK7 Are Phosphorylated in Forskolin-stimu-
lated HEK-293 Cells—Phosphorylation of the wild-type pro-
teins and the kinase-inactive mutants was assessed in trans-
fected HEK-293 cells to determine whether cAMP-dependent
phosphorylation of GRK1 and GRK7 occurs in intact cells.
After labeling with 32P-orthophosphate, cells were treated with
forskolin to elevate cAMP levels and activate PKA. Wild-type
GRK1 and GRK7 immunoprecipitated from forskolin-treated
cells had increased levels of phosphorylation in comparison
with cells treated with vehicle alone (Fig. 4A). The kinase-
inactive mutants, K219R-GRK1 and K220R-GRK7, were also
phosphorylated in a forskolin-dependent manner. The expres-
sion levels of wild-type and mutant FLAG-tagged GRK1 and
GRK7 were assessed by Western blot analysis using anti-FLAG
monoclonal antibodies (Fig. 4B). The expression of K219R-
GRK1 and K220R-GRK7 is reduced in comparison to the wild-
type proteins, leading to the lower levels of phosphorylation by
PKA observed for these mutants in Fig. 4A.
PKA Phosphorylates GRK1 on Ser21—Using the computer
program, NetPhos (www.cbs.dtu.dk/services/NetPhos/) (46),
amino acid sequence analysis of GRK1 predicts the presence of
five potential PKA phosphorylation sites. Chemical cleavage of
PKA-phosphorylated GRK1 into large peptides with either for-
mic acid or iodosobenzoic acid revealed that GRK1 is phospho-
rylated on the amino-terminal domain between amino acid
residues 1–128 (data not shown). This region of GRK1 contains
two potential PKA phosphorylation sites, Ser21 and Ser53.
GRK1 mutants S21A and S53A were compared with wild-type
and kinase-inactive GRK1 (K219R-GRK1) by phosphopeptide
mapping. The major autophosphorylation sites in GRK1 are
Ser488 and Thr489 (31, 36); the tryptic phosphopeptide maps of
FIG. 2. Kinetic parameters of human GRK1 and GRK7. A, the
Km and Vmax for ATP was determined using 50 nM GRK1 or GRK7, 10
M rhodopsin, and the indicated concentrations of [-32P]ATP (500–
1000 cpm/pmol) (n  5). B, the Km and Vmax for rhodopsin were deter-
mined using 50 nM GRK1 or GRK7, 300 M [-32P]ATP (500–1000
cpm/pmol), and the indicated concentrations of rhodopsin (n  4).
Phosphorylation reactions were performed in triplicate for 2 min at
30 °C as described under “Experimental Procedures” and graphed as
the average of the indicated number of experiments. Error bars repre-
sent S.E.
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wild-type GRK1 (Fig. 5A) likely represent a mixture of mono-
phosphorylated and diphosphorylated peptides (peptides 1–3).
Tryptic phosphopeptide maps were also prepared from wild
type and mutant GRK1 phosphorylated by PKA in vitro. Phos-
phorylation of wild-type GRK1 by PKA, generates an addi-
tional phosphopeptide, peptide 4 (Fig. 5B). The map of K219R-
GRK1 is missing peptides 1–3, since this kinase-inactive
mutant does not undergo autophosphorylation but displays
peptide 4 because it is phosphorylated by PKA (Fig. 5C). Al-
though S21A-GRK1 undergoes autophosphorylation (Fig. 5D),
it is not phosphorylated by PKA, as evident from the absence of
peptide 4 in Fig. 5E. Phosphorylation of GRK1-S53A by PKA
was similar to wild-type GRK1, indicating that Ser53 is not a
substrate for PKA (data not shown). Therefore, Ser21 appears
to be the only residue in GRK1 phosphorylated by PKA in vitro.
To determine whether GRK1 can be phosphorylated by PKA
at Ser21 in cells, HEK-293 cells expressing wild-type or mutant
GRK1 were radiolabeled with [32P]orthophosphate and treated
with forskolin or vehicle (Fig. 6). GRK1 immunoprecipitated
from cell lysates was digested with trypsin for phosphopeptide
mapping. Similar to the results of the in vitro phosphorylation
experiments in Fig. 5, autophosphorylation of wild-type GRK1
and S21A-GRK1 results in a mixture of monophosphorylated
and diphosphorylated phosphopeptides (peptides 1–3; Fig. 6, A,
B, D, and E), whereas K219R-GRK1 is not autophosphorylated
(Fig. 6C). Forskolin treatment increased levels of peptide 4 in
cells expressing wild-type GRK1 and K219R-GRK1 (Figs. 6, B
and C). In contrast, S21A-GRK1 does not display forskolin-de-
pendent phosphorylation (Fig. 6E), implicating Ser21 as the site
of phosphorylation by PKA. In the absence of forskolin, peptide
4 is detectable at very low levels in wild-type GRK1 (Fig. 6A),
due either to weak autophosphorylation of Ser21, as described
previously (36), or to basal activity of PKA in HEK-293 cells.
Collectively, these results demonstrate that GRK1 is phospho-
rylated by PKA at Ser21 in vitro and in a forskolin-dependent
manner in HEK-293 cells.
PKA Phosphorylates GRK7 on Ser23 and Ser36—To deter-
mine the sites on GRK7 that are phosphorylated by PKA, seven
potential substrate sites (identified by NetPhos as described
above) were mutated to Ala or Glu and the effect on phospho-
rylation of GRK7 by PKA measured in vitro. Comparison of
Ser23 and Ser36 single point mutants, S23A and S36A, with
wild-type GRK7 revealed a partial reduction in phosphoryla-
tion of the mutants by PKA (Fig. 7). Ser23 and Ser36 appear to
be the only PKA phosphorylation sites, since the GRK7 double
mutants, S23A/S36A and S23E/S36E, were not phosphorylated
by PKA (Fig. 7). In contrast, mutation of the other five potential
PKA phosphorylation sites to alanine (S333A, T353A, S441A,
S445A, and T537A) did not reduce PKA phosphorylation (data
not shown). Autophosphorylation of wild-type GRK7 and the
GRK7 mutants was similar, suggesting that mutation of Ser23
TABLE I
Comparison of the kinetic parameters of GRK1 and GRK7
The Km and Vmax for ATP and rhodopsin were determined for GRK1 and GRK7 by nonlinear regression as described in the legend to Fig. 2. The
values for the kinetic parameters are the average of five experiments (ATP) and four experiments (rhodopsin). The kcat (turnover number) and
kcat/Km (specificity constant) were determined assuming molecular weights of 63.5 kDa and 62.2 kDa for GRK1 and GRK7, respectively. The kinetic
parameters of bovine GRK1 for bovine rhodopsin in membranes (31) and in detergent extracts (32) were included for comparison. N/A, not
available.
Km
ATP Rhodopsin Vmax kcat kcat/Km
M nmol/min/mg s1 s1 M1
GRK7 21.4  5.6 1.9  0.4 915.7  64.5 1.0  0.2 5.5  0.4  105
GRK1 10.6  4.0 3.5  0.7 1132.0  84.2 1.2  0.2 3.6  0.3  105
GRK1 (31) 7  2 4  2 450  52 N/A N/A
GRK1 (32) N/A 0.45  0.04 39  2 0.04 0.9
FIG. 3. Phosphorylation of GRK1 and GRK7 by PKA in vitro. A,
wild-type (WT) GRK1 and GRK7 and kinase inactive mutants of GRK1
(K219R) and GRK7 (K220R) were incubated without () or with () the
catalytic subunit of PKA and 150 M [-32P]ATP (500–1000 cpm/pmol)
for 30 min at 30 °C. B, GRK7 autophosphorylation site mutants (S490A
and S490E) were incubated with 150 M [-32P]ATP for 60 min at 30 °C
in the absence () or presence () of PKA. The phosphorylated proteins
were separated by SDS-PAGE, and phosphorylation was visualized by
phosphorimage analysis.
FIG. 4. Phosphorylation of GRK1 and GRK7 by PKA in HEK-
293 cells. A, wild-type (WT) and kinase-inactive GRK1 (K219R) and
GRK7 (K220R) were expressed in HEK-293 cells and labeled with
[32P]orthophosphate. Nontransfected (NT) cells were used as a negative
control. Cells were treated with 25 M forskolin in Me2SO () or Me2SO
alone () for 15 min and FLAG-tagged GRKs were immunoprecipitated
from cell lysates using anti-FLAG affinity resin. The phosphorylated
proteins were separated by SDS-PAGE and visualized using phospho-
rimage analysis. B, Western blot analysis using an anti-FLAG mono-
clonal antibody was performed to compare the expression levels of
wild-type and mutant GRK1 and GRK7.
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and Ser36 did not affect the intrinsic kinase activity of GRK7.
Wild-type and mutant GRK7 were phosphorylated in vitro,
digested with chymotrypsin, and analyzed by two-dimensional
chromatography to confirm the identity of the phosphorylation
sites. Autophosphorylation of wild-type GRK7 results in one
phosphopeptide (peptide 1; Fig. 8A), consistent with our earlier
finding that GRK7 possesses only one autophosphorylation
site, Ser490 (Fig. 3B). Phosphorylation by PKA results in two
prominent phosphopeptides (peptides 2 and 3; Fig. 8B) that are
distinct from the phosphopeptide generated by autophospho-
rylation. Compared with wild-type GRK7, S23A-GRK7 (Fig.
8C) and S36A-GRK7 (Fig. 8D) each lack one of the PKA-de-
pendent phosphopeptides (peptides 3 and 2, respectively),
while the double Ala mutant (S23A/S36A-GRK7), which can be
autophosphorylated (Fig. 8E), lacks both PKA-dependent phos-
phopeptides (Fig. 8F). These experiments confirm that Ser23
and Ser36 are phosphorylated by PKA in vitro.
Chymotryptic phosphopeptide maps derived from radiola-
beled HEK-293 cells expressing GRK7 (Fig. 9) are similar to
those derived from GRK7 phosphorylated in vitro (Fig. 8).
Consistent with Ser490 as the sole autophosphorylation site in
GRK7, only one phosphopeptide (peptide 1) was observed when
wild-type GRK7 was isolated from vehicle-treated cells and
subjected to phosphopeptide mapping (Fig. 9A). In contrast,
maps of wild-type GRK7 isolated from forskolin-treated cells
contained two additional phosphopeptides (peptides 2 and 3;
Fig. 9B). Chymotryptic maps of the kinase-inactive mutant
(K220R-GRK7) isolated from forskolin-treated cells lacked pep-
tide 1 but displayed peptides 2 and 3 (Fig. 9C), consistent with
the identification of peptide 1 as an autophosphorylation site
and peptides 2 and 3 as sites phosphorylated by PKA.
Phosphorylation by PKA Inhibits GRK1 and GRK7 Activity
in Vitro—To determine whether phosphorylation by PKA al-
ters GRK1 activity, wild-type GRK1 and the mutants S21A-
GRK1 and S21E-GRK1 were preincubated for 10 min in the
presence or absence of ATP and PKA, then rhodopsin was
added as a substrate for an additional 2 min to measure the
activity of the kinases. Autophosphorylation did not alter the
overall activity of GRK1, whereas phosphorylation of GRK1 by
PKA reduced the ability of wild-type GRK1 to phosphorylate
rhodopsin by more than 50% (Fig. 10A). The mutant S21A-
GRK1 phosphorylated rhodopsin at levels that were slightly
reduced compared wild-type GRK1. However, S21E-GRK1
demonstrated dramatically reduced ability to phosphorylate
FIG. 7. Phosphorylation of wild-type (WT) and mutant GRK7.
Phosphorylation of wild-type GRK7 was compared with mutant pro-
teins possessing single (S23A, S36A, S23E, and S36E) or double (S23A/
S36A and S23E/S36E) Ala or Glu substitutions at Ser23 and Ser36.
Wild-type and mutant GRKs were incubated with 10 M [-32P]ATP (10
Ci/reaction) in the presence () or absence () of PKA for 1 h at 30 °C.
Phosphorylated proteins were separated by SDS-PAGE and visualized
by phosphorimage analysis.
FIG. 5. Two-dimensional chromatography of GRK1 phospho-
rylated in vitro. Wild-type (WT) and mutant GRKs were phosphoryl-
ated as described under “Experimental Procedures” and digested with
trypsin for phosphopeptide mapping. The tryptic phosphopeptides were
separated by TLE and TLC as described under “Experimental Proce-
dures.” Phosphorylation of wild-type GRK1 was examined in the ab-
sence (A) or presence (B) of PKA. Phosphorylation of K219R-GRK1 was
examined in the presence of PKA (C), while phosphorylation of S21A-
GRK1 was examined in the absence (D) or presence (E) of PKA. The
phosphorylated peptides were detected by autoradiography. The aster-
isk indicates the peptide origin. The  symbol indicates the absence of
specific phosphopeptides compared with wild-type GRK1.
FIG. 6. Two-dimensional chromatography of GRK1 phospho-
rylated in situ. Wild-type (WT) GRK1, S21A-GRK1, and K219R-GRK1
were expressed in HEK-293 cells. Cells were labeled with
[32P]orthophosphate and treated with Me2SO (A and D) or 25 M fors-
kolin in Me2SO (B, C, and E) for 15 min as described under “Experi-
mental Procedures.” GRKs were immunoprecipitated from cell lysates
with anti-FLAG monoclonal antibodies and analyzed by TLE and TLC
as described under “Experimental Procedures.” The asterisk indicates
the peptide origin. The  symbol indicates the absence of specific
phosphopeptides compared with wild-type GRK1.
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rhodopsin, suggesting that substitution of the negatively
charged residue, glutamic acid, for serine mimicked phospho-
rylation by PKA. Both S21A-GRK1 and S21E-GRK1 activities
were insensitive to phosphorylation by PKA, consistent with
our observation that Ser21 is the only PKA phosphorylation site
on GRK1. Since the levels of autophosphorylation are similar
for wild-type GRK1, S21A-GRK1, and S21E-GRK1 (Fig. 10B),
their intrinsic activities appear to be unaffected by
mutagenesis.
The effect of phosphorylation by PKA on the activity of
wild-type and mutant GRK7 was also examined using rhodop-
sin as a substrate. Phosphorylation by PKA inhibited the abil-
ity of wild-type GRK7 to phosphorylate rhodopsin by 50% (Fig.
11), similar to the effect of phosphorylation by PKA observed
for GRK1. In comparison, S23A and S36A mutants were unaf-
fected by preincubation with PKA. The double mutant, S23A/
S36A-GRK7, phosphorylated rhodopsin at higher levels than
the wild-type protein, whereas S23A-GRK7 and S36A-GRK7
had activities similar to wild-type GRK7. In contrast, S23E/
S36E-GRK7 had reduced activity compared with wild type
GRK7 and was also unaffected by a preincubation with PKA.
The mutants S23E-GRK7 and S36E-GRK7 also had reduced
activities compared with wild-type GRK7. The activities of the
single and double S23E and S36E mutants suggest that the
Glu substitutions of GRK7 mimic phosphorylation by PKA.
Autophosphorylation of the GRK7 Ser23 and Ser36 mutants was
similar to wild-type GRK7 (Fig. 7), suggesting that mutagene-
sis did not interfere with their intrinsic kinase activities.
Several other proteins localized to photoreceptor cell outer
segments have been shown to be substrates for PKA, including
phosducin, RGS9–1, PDE, and PDE (25, 47–49). Therefore,
we were interested to know whether PKA present in rod outer
segments would phosphorylate GRK1 and GRK7. Rod outer
segments were isolated from dark-adapted frozen bovine retina
FIG. 8. Two-dimensional chromatography of GRK7 phospho-
rylated in vitro. Wild-type (WT) and mutant GRKs were phosphoryl-
ated as described in the legend to Fig. 7 and digested with chymotryp-
sin. The chymotryptic peptides were separated by TLE and TLC as
described under “Experimental Procedures.” Wild-type GRK7 was
phosphorylated in the absence (A) and presence (B) of PKA. S23A-
GRK7 (C) and S36A-GRK7 (D) were phosphorylated in the presence of
PKA. S23A/S36A-GRK7 was phosphorylated in the absence (E) and
presence (F) of PKA. Phosphopeptides were visualized by autoradiog-
raphy. The asterisk indicates the peptide origin. The  symbol indicates
the absence of specific phosphopeptides compared with wild-type
GRK1.
FIG. 9. Two-dimensional chromatography of GRK7 phospho-
rylated in situ. Wild-type (WT) GRK7 (A and B) and K220R-GRK7 (C)
were expressed in HEK-293 cells and labeled with [32P]orthophosphate
as described under “Experimental Procedures.” Cells were treated with
Me2SO (A) or 25 M forskolin in Me2SO (B and C) for 15 min. GRKs
were immunoprecipitated from cell lysates with anti-FLAG monoclonal
antibodies, and the phosphorylated proteins were digested with chymo-
trypsin for analysis by TLE and TLC as described under “Experimental
Procedures.” The asterisk indicates the peptide origin. The  symbol
indicates the absence of specific phosphopeptides compared with wild-
type GRK1.
FIG. 10. Phosphorylation by PKA inhibits GRK1 activity. A,
wild-type (WT) GRK1, S21A-GRK1, or S21E-GRK1 (50 nM, final con-
centration) were incubated with 300 M [-32P]ATP (500–1000 cpm/
pmol) in the absence () or presence () of PKA in vitro for 10 min at
30 °C prior to the addition of UROS (containing 2 M rhodopsin, final
concentration) in a 25 l of reaction volume for 2 min. Levels of phos-
phorylation were quantified by Cerenkov counting. Phosphorylation of
rhodopsin in the dark was subtracted from phosphorylation in the light
and normalized to the levels of rhodopsin phosphorylation by wild-type
GRK1 preincubated in the absence of ATP or PKA (ATP/PKA). The
values for phosphorylation of wild-type and mutant GRK1 in the dark
were 101  24 nmol/min/mg of kinase. In contrast, the values in the
light range from 194  29 to 548  75. The results represent the
average of three to four experiments. Error bars represent S.E. B,
wild-type GRK1, S21A-GRK1, and S21E-GRK1 were incubated with
[-32P]ATP for 60 min at 30 °C and examined by phosphorimage
analysis.
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and incubated with [-32P]ATP and purified FLAG-tagged
GRK1 or GRK7 in the presence or absence of Bt2cAMP (Fig.
12). Wild-type GRK1 and GRK7 demonstrated enhanced phos-
phorylation in the presence of Bt2cAMP. This phosphorylation
was decreased in the presence of H-89, an inhibitor of PKA. The
kinase-inactive mutants, K219R-GRK1 and K220R-GRK7,
could only be phosphorylated in the presence of Bt2cAMP and
phosphorylation was abolished in the presence of H-89. West-
ern blot analysis demonstrated that equal amounts of FLAG-
tagged GRK1 and GRK7 proteins were isolated from the reac-
tion mixtures. These data indicate that GRK1 and GRK7 can
be phosphorylated in rod outer segment extracts and provides
evidence that this potential regulatory mechanism may be
relevant in vivo.
DISCUSSION
In humans and monkeys, only GRK1 is expressed in rods,
whereas cones express both GRK1 and GRK7 (7, 8, 50, 51).
Deficiencies in their expression contribute to impaired vision
observed in patients with Oguchi disease and enhanced S cone
syndrome (9, 52). A biochemical comparison of GRK1 and
GRK7 is critical to understanding their roles in desensitization
in cones and may provide insight into the functional conse-
quences of their disparate expression patterns in mammals
(6–8). We have compared the Km and Vmax of GRK1 and GRK7
for rhodopsin and ATP and provide the first evidence that these
two kinases are similar in their affinity and catalytic activity.
Furthermore, our results for human GRK1 are similar to those
previously reported for the phosphorylation of rhodopsin by
bovine GRK1 (31). Although mammalian GRK1 is farnesylated
in vivo (54), and GRK7 is predicted to be geranylgeranylated,
based on the sequence of the carboxyl-terminal CAAX motif (6,
7), our results suggest that differences in amino acid sequence
(only 47% overall identity) and isoprenyl modification do not
significantly affect their activities toward a model substrate.
This conclusion is in agreement with that of Inglese and co-
workers (55), who reported that exchange of the farnesyl for a
geranylgeranyl CAAX motif on GRK1 alters membrane associ-
ation but not the ability to phosphorylate rhodopsin.
We demonstrate for the first time that PKA phosphorylates
serine residues on GRK1 and GRK7 in vitro, using either
commercially supplied PKA catalytic subunit or isolated rod
outer segments containing the PKA holoenzyme stimulated by
Bt2cAMP. We have also shown that GRK1 and GRK7 ex-
pressed in HEK-293 cells are phosphorylated when the cells
are treated with forskolin. PKC and CaMKII, which phospho-
rylate the retina-specific proteins RGS9–1 and phosducin, re-
spectively (40, 45, 56), did not phosphorylate GRK1 or GRK7 in
vitro (data not shown). Therefore, phosphorylation of GRK1
and GRK7 by PKA appears to be selective and suggests a novel
mechanism for the regulation of these kinases by cAMP. Phos-
phorylation significantly decreases the ability of these kinases
to phosphorylate rhodopsin. The sites phosphorylated by PKA,
Ser21 in GRK1 and Ser23 and Ser36 in GRK7, are localized to
similar positions in the amino termini (residues 1–192) (Fig
13). These domains share only 30% amino acid identity,
whereas the catalytic and carboxyl-terminal domains share 56
and 52% identity, respectively. Despite the low sequence iden-
tity in the amino termini, the similar positions of these PKA
FIG. 11. Phosphorylation by PKA inhibits GRK7 activity. Wild-
type (WT) GRK7 and Ser23 and Ser36 GRK7 mutants (50 nM, final
concentration) were incubated in the absence () or presence () of
PKA and 300 M [-32P]ATP (500–1000 cpm/pmol) for 10 min at 30 °C
prior to the addition of UROS (containing 2 M rhodopsin, final concen-
tration) in a 25-l reaction volume for 2 min. Phosphorylation was
evaluated as described in the legend for Fig. 10. The values for phos-
phorylation of wild-type and mutant GRK1 were 82  17 nmol/
min/mg of kinase. In contrast, the values in the light ranged from 262 
52 nmol/min/mg of kinase to 591  64 nmol/min/mg of kinase for
wild-type and mutant GRK7. The results represent the average of 3–10
experiments. Error bars represent S.E.
FIG. 12. cAMP-dependent phosphorylation of GRK1 and GRK7
by rod outer segments. FLAG-tagged wild-type (WT) GRK1 and the
kinase-inactive mutant, K219R-GRK1 (A), or wild-type GRK7 and the
kinase-inactive mutant, K220R-GRK7 (B), were incubated with bovine
ROS prepared as described under “Experimental Procedures” in the
presence () or absence () of dibutyryl cAMP (db-cAMP) and H-89, an
inhibitor of PKA. Phosphorylation was performed in the dark for 30 min
at 30 °C in the presence of 5 M [-32P]ATP (30 Ci). The FLAG-tagged
GRKs were immunoprecipitated from the ROS, separated by SDS-
PAGE, and transferred to nitrocellulose. The level of phosphorylation
was assessed by phosphorimage analysis, and the levels of GRK1 and
GRK7 were assessed by Western blot analysis using the anti-FLAG
monoclonal antibody, M2, and a chemiluminescent secondary antibody
detection system as described under “Experimental Procedures.” Ar-
rowheads represent the positions of FLAG-tagged GRK1 and GRK7.
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phosphorylation sites suggest a common function. Substitution
of Ser21 in GRK1 and both Ser23 and Ser36 in GRK7 with
glutamic acid appears to mimic phosphorylation by PKA, re-
sulting in reduced ability of these mutants to phosphorylate
rhodopsin. In contrast, the alanine mutants, S21A-GRK1 and
S23A/S36A-GRK7, phosphorylate rhodopsin to similar or
higher levels than the wild type proteins. None of the glutamic
acid or alanine mutants is phosphorylated by PKA, and PKA
does not affect the ability of these mutants to phosphorylate
rhodopsin, indicating that we have correctly identified the ma-
jor phosphorylation sites. Collectively, these data suggest that
phosphorylation of GRK1 and GRK7 by PKA inhibits phospho-
rylation of rhodopsin, possibly by disrupting their interaction
with substrates. This hypothesis is consistent with observa-
tions by others that the amino-terminal domain of GRK1 reg-
ulates rhodopsin binding (57, 58). An alternative hypothesis,
that phosphorylation of GRK1 and GRK7 by PKA reduces their
intrinsic activities, is unlikely, since mutation of the phospho-
rylation sites to alanine or glutamic acid does not affect auto-
phosphorylation of either kinase. Phosphorylation by PKA may
also be a step in a larger regulatory mechanism involving
calcium binding proteins such as recoverin, since the amino
terminus of GRK1 is the site of negative regulation by recov-
erin (5). Phosphorylation may also control the binding of other,
as yet unidentified, regulatory proteins. We cannot entirely
rule out the possibility that cGMP-dependent protein kinase
(PKG) phosphorylates GRK1 and GRK7 in the retina, because
the consensus sequences for substrate phosphorylation are so
similar for PKG and PKA (59). However, PKA is generally
expressed at much higher concentrations than PKG in most
cell types (59) and colocalizes with other photoreceptor cell
substrates in rod outer segments (see below) (25, 47–49). We
observed that forskolin, a specific activator of adenylyl cyclase,
induces phosphorylation of these GRKs in HEK-293 cells and
that H-89, an inhibitor that is 10-fold more selective for PKA
over PKG (60), blocks Bt2cAMP-stimulated phosphorylation of
GRKs using rod outer segments. These data strongly suggest
that PKA functions to phosphorylate these GRKs. Future work,
perhaps using conditional knock-outs of these two kinases in
mice, would be necessary to determine whether PKG can phos-
phorylate these GRKs in vivo.
Several other photoreceptor cell proteins have been identi-
fied as PKA substrates, including phosducin, RGS9–1, PDE,
and PDE (25, 47–49). Therefore, these proteins may be reg-
ulated by light-dependent changes in cAMP levels, which are
well documented in vertebrate photoreceptor cells (12, 13, 15,
61). Calmodulin (CaM), activated by higher Ca2 concentra-
tions in the dark, stimulates cAMP synthesis by adenylyl cy-
clase Type I (AC1) (12, 14, 62, 63). Both phosducin and RGS9–1
demonstrate increased phosphorylation in the dark, consistent
with the higher levels of cAMP in photoreceptor cells observed
under these conditions (25, 48), although recent work on phos-
ducin suggests that higher cAMP in the dark may not always
involve regulation by Ca2 (35). Rods and cones also display a
circadian regulation of cAMP levels through a complex mech-
anism that has yet to be fully elucidated. For example, tran-
scription of AC1 has been shown to be circadian in rat rods,
demonstrating greater activity at night (65). Therefore, cAMP
levels are generally higher at night and may enhance the
phosphorylation of photoreceptor cell substrates by PKA. An-
other mechanism for circadian regulation of PKA activity may
be via dopamine, the major catecholamine in the retina. Do-
pamine released from amacrine and interplexiform cells (66,
67) as part of the circadian rhythm in the retina (68–70) acts on
rod and cone cells through D2/D4 dopamine receptors (70) to
inhibit adenylyl cyclase activity and reduce cAMP levels during
the day (13, 71–74). We propose that PKA phosphorylates
GRK1 and GRK7 when cAMP levels in photoreceptor cell are
elevated, either in direct response to the absence of light in
photoreceptor cells or through circadian regulation as de-
scribed above. Under these conditions, GRK1 and GRK7 would
have reduced ability to phosphorylate their substrates. When
the retina is exposed to light, cAMP levels fall, allowing PKA
substrates in photoreceptor cells, including GRK1 and GRK7,
to be dephosphorylated. This would presumably increase the
activities of these GRKs, enhancing phosphorylation of their
substrates. Since cAMP does not appear to affect phototrans-
duction in lizard rods after a flash stimulus (75), this signaling
pathway may be more important for photoreceptor cells to
adapt to persistent, higher light intensities.
Recent studies have suggested that the subcellular localization
and enzymatic activities of several other GRKs are regulated by
phosphorylation (16–19, 76, 77). For example, PKA phosphoryl-
ates the carboxyl terminus of GRK2 at Ser685, causing enhanced
binding of GRK2 to G subunits and translocation of GRK2 to
the membrane (78). PKC, Src, and extracellular signal-regulated
kinase 1/mitogen-activated protein kinase (ERK1/MAPK) also
regulate the activities of some GRK family members (16, 79–86).
The data presented here provide new insights into a potential
mechanism for regulating the activities of GRK1 and GRK7 in
response to light-dependent or circadian changes in Ca2 and
cAMP levels. For GRK1, the most likely substrate in rods is
rhodopsin (5), while in cones GRK1 and GRK7 phosphorylate
cone opsins, based on recent work from our own (10, 64) and other
laboratories (53). However, the possibility that other GPCRs and
nonreceptor proteins important in photoreceptor cell metabolism,
survival, and function are substrates for these kinases should not
be overlooked. Ongoing studies seek to uncover the role of phos-
phorylation by PKA in GRK1 and GRK7 function in the verte-
brate retina.
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